Titan Pharmaceuticals (TTNP) Competitors $4.07 -1.06 (-20.66%) Closing price 03:59 PM EasternExtended Trading$4.16 +0.09 (+2.09%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. CARM, CTXR, ATHA, CASI, PRPH, ALLR, MTEX, EQ, ERNA, and PMNShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Carisma Therapeutics (CARM), Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), CASI Pharmaceuticals (CASI), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Mannatech (MTEX), Equillium (EQ), Ernexa Therapeutics (ERNA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Carisma Therapeutics Citius Pharmaceuticals Athira Pharma CASI Pharmaceuticals ProPhase Labs Allarity Therapeutics Mannatech Equillium Ernexa Therapeutics Promis Neurosciences Carisma Therapeutics (NASDAQ:CARM) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Does the media refer more to CARM or TTNP? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Carisma Therapeutics' average media sentiment score of 1.94 beat Titan Pharmaceuticals' score of 1.87 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Very Positive Titan Pharmaceuticals Very Positive Do institutionals & insiders believe in CARM or TTNP? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate CARM or TTNP? Carisma Therapeutics presently has a consensus target price of $1.93, indicating a potential upside of 396.13%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Carisma Therapeutics is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, CARM or TTNP? Titan Pharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.83-$60.48M-$1.56-0.25Titan Pharmaceuticals$180K20.58-$4.71M-$4.59-0.89 Which has more volatility & risk, CARM or TTNP? Carisma Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Is CARM or TTNP more profitable? Titan Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Titan Pharmaceuticals N/A -145.92%-129.20% SummaryCarisma Therapeutics beats Titan Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.69M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.8921.0428.0720.05Price / Sales20.58284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book1.528.378.665.87Net Income-$4.71M-$55.19M$3.25B$258.55M7 Day Performance-9.15%5.89%4.20%2.23%1 Month Performance-6.65%17.63%10.82%12.76%1 Year Performance-30.31%5.09%34.70%19.36% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.304 of 5 stars$4.07-20.7%N/A-14.2%$4.69M$180K-0.8910Positive NewsGap UpHigh Trading VolumeCARMCarisma Therapeutics3.1687 of 5 stars$0.39-0.6%$1.93+393.8%-63.5%$16.39M$19.63M-0.2520Positive NewsCTXRCitius Pharmaceuticals3.2695 of 5 stars$1.44-5.9%$53.00+3,580.6%-92.7%$16.27MN/A0.0020Positive NewsATHAAthira Pharma3.7585 of 5 stars$0.43+5.6%$11.25+2,510.2%-86.0%$15.93MN/A-0.2140Positive NewsUpcoming EarningsCASICASI Pharmaceuticals3.9666 of 5 stars$1.22-3.2%$4.00+227.9%-78.2%$15.50M$28.54M-0.48180Gap UpPRPHProPhase Labs0.3854 of 5 stars$0.40+10.3%N/A-86.4%$15.18M$6.77M0.00130Gap UpALLRAllarity Therapeutics0.7302 of 5 stars$0.97-2.3%N/A-81.0%$15.03MN/A0.0010Positive NewsMTEXMannatech1.0455 of 5 stars$8.08+2.8%N/A+11.0%$14.94M$115.04M-80.80250News CoverageGap DownEQEquillium2.9663 of 5 stars$0.41-0.2%$3.00+624.5%-58.4%$14.83M$41.10M-1.0640Positive NewsGap UpERNAErnexa Therapeutics1.1012 of 5 stars$1.96-1.0%N/A-92.7%$14.58M$580K-0.2410Positive NewsGap UpPMNPromis Neurosciences2.9631 of 5 stars$1.12+154.5%$4.33+286.9%-56.9%$14.39MN/A-22.405News CoverageAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Carisma Therapeutics Alternatives Citius Pharmaceuticals Alternatives Athira Pharma Alternatives CASI Pharmaceuticals Alternatives ProPhase Labs Alternatives Allarity Therapeutics Alternatives Mannatech Alternatives Equillium Alternatives Ernexa Therapeutics Alternatives Promis Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TTNP Stock Alerts